What is Hepion Pharmaceuticals Inc's earnings per share (EPS)?

Hepion Pharmaceuticals Inc (HEPA) reported diluted earnings per share of $-0.88 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hepion Pharmaceuticals Inc Financials

HEPA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Hepion Pharmaceuticals Inc (HEPA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HEPA FY2025 2026-05-14

Equity repairs now come from external financing while cash burn has fallen sharply after research spending was largely wound down.

FY2025’s return to positive equity was financed, not earned: a $4.8M financing inflow more than covered $3.3M of operating cash burn, helping equity swing from negative in FY2024 to $2.7M. At the same time, liabilities were cut from $3.5M to $402K, so the cleaner balance sheet reflects recapitalization rather than operating self-funding.

The cost structure changed materially across FY2023 to FY2025: R&D spending fell from $35.6M to $446K, while SG&A was still $3.3M. That means the remaining loss base is now much less about running an active research program and much more about maintaining the company’s corporate infrastructure.

This is an asset-light cash burn story, not a capital-spending story. Investing outflows were only $132K in FY2025 versus $3.3M of operating cash burn, so cash preservation here depends far more on controlling operating expense than on trimming equipment or facility investment.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Hepion Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Hepion Pharmaceuticals Inc carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.25, Hepion Pharmaceuticals Inc holds $10.25 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Hepion Pharmaceuticals Inc generates a -310.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Hepion Pharmaceuticals Inc passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, Hepion Pharmaceuticals Inc generates $0.40 in operating cash flow (-$3.3M OCF vs -$8.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$8.3M

Hepion Pharmaceuticals Inc reported -$8.3M in net income in fiscal year 2025.

EPS (Diluted)

$-0.88

Hepion Pharmaceuticals Inc earned $-0.88 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.8M

YoY+349.8%

5Y CAGR-46.2%

10Y CAGR-8.7%

Hepion Pharmaceuticals Inc held $1.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

12M

Hepion Pharmaceuticals Inc had 12M shares outstanding in fiscal year 2025. This represents an increase of 8249.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-310.3%

5Y CAGR-260.1pp

10Y CAGR+106.9pp

Hepion Pharmaceuticals Inc's ROE was -310.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$446K

5Y CAGR-48.2%

10Y CAGR-25.5%

Hepion Pharmaceuticals Inc invested $446K in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

N/A

HEPA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$446K	N/A	$35.6M+7.1%	$33.3M+63.1%	$20.4M+70.0%	$12.0M
SG&A Expenses	$3.3M-55.8%	$7.5M-22.0%	$9.6M-7.1%	$10.3M+3.4%	$10.0M+22.8%	$8.1M
Operating Income	-$4.2M	N/A	-$48.4M-6.5%	-$45.5M-49.6%	-$30.4M-50.9%	-$20.1M
Interest Expense	N/A	N/A	$9K-6.9%	$10K+14.7%	$9K-71.6%	$31K
Income Tax	N/A	-$3.0M-625.9%	-$409K+85.8%	-$2.9M	$0-100.0%	$31K
Net Income	-$8.3M	N/A	-$48.9M-15.9%	-$42.2M-29.0%	-$32.7M-60.8%	-$20.4M
EPS (Diluted)	$-0.88	$-107.35+82.6%	$-616.07	$-11.90	$-0.47+77.6%	$-2.10

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$70K	N/A	N/A	$423K+1803.7%	$22K	N/A	$2.8M-61.3%	$7.1M
SG&A Expenses	$729K	N/A	$528K-42.6%	$919K-26.9%	$1.3M	N/A	$1.7M+24.0%	$1.4M
Operating Income	-$799K	N/A	-$528K+69.8%	-$1.7M-36.3%	-$1.3M	N/A	-$4.5M+47.6%	-$8.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$811K	N/A	-$473K+54.7%	-$1.0M+82.9%	-$6.1M	N/A	-$4.9M-24.0%	-$3.9M
EPS (Diluted)	$-0.07	N/A	$-0.04+55.6%	$-0.09+95.8%	$-2.15	N/A	$-36.21-6.5%	$-34.00

HEPA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.1M+90.2%	$1.6M-91.1%	$18.1M-70.0%	$60.2M-41.8%	$103.6M+112.9%	$48.6M
Current Assets	$3.1M+90.2%	$1.6M-90.8%	$17.5M-69.0%	$56.5M-42.0%	$97.5M+128.6%	$42.6M
Cash & Equivalents	$1.8M+349.8%	$406K-97.3%	$14.8M-71.1%	$51.2M-44.0%	$91.3M+124.3%	$40.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$1.9M0.0%	$1.9M
Total Liabilities	$402K-88.4%	$3.5M-67.8%	$10.8M+4.1%	$10.4M-1.6%	$10.6M+29.9%	$8.1M
Current Liabilities	$299K-90.5%	$3.1M-40.6%	$5.3M-32.9%	$7.9M-3.9%	$8.2M+76.0%	$4.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.7M+243.2%	-$1.9M-125.6%	$7.3M-85.4%	$49.9M-46.4%	$93.0M+129.5%	$40.5M
Retained Earnings	-$246.1M-3.5%	-$237.8M-5.9%	-$224.6M-27.8%	-$175.7M-31.6%	-$133.5M-28.2%	-$104.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$2.7M-11.9%	$3.1M-17.9%	$3.7M-17.0%	$4.5M-28.7%	$6.3M+291.5%	$1.6M-56.6%	$3.7M-38.2%	$6.0M
Current Assets	$2.7M-11.9%	$3.1M-17.9%	$3.7M-17.0%	$4.5M-28.7%	$6.3M+291.5%	$1.6M-54.3%	$3.5M-35.6%	$5.5M
Cash & Equivalents	$2.6M+42.4%	$1.8M-21.2%	$2.3M-20.6%	$2.9M-36.2%	$4.6M+1028.5%	$406K-72.9%	$1.5M-29.2%	$2.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$849K+110.9%	$402K-3.2%	$416K-41.3%	$709K-70.8%	$2.4M-30.3%	$3.5M-15.6%	$4.1M+68.4%	$2.4M
Current Liabilities	$736K+145.7%	$299K-13.8%	$347K-41.4%	$593K-36.7%	$936K-70.2%	$3.1M+15.8%	$2.7M+178.4%	$976K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.9M-30.4%	$2.7M-19.8%	$3.3M-12.4%	$3.8M-2.5%	$3.9M+309.1%	-$1.9M-558.2%	$407K-88.6%	$3.6M
Retained Earnings	-$246.9M-0.3%	-$246.1M-0.3%	-$245.4M-0.2%	-$245.0M-0.4%	-$243.9M-2.6%	-$237.8M-0.7%	-$236.3M-2.1%	-$231.4M

HEPA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.3M	N/A	-$40.9M-17.0%	-$35.0M-12.0%	-$31.2M-93.2%	-$16.2M
Capital Expenditures	N/A	N/A	$14K-12.4%	$16K-87.5%	$130K+48.2%	$88K
Free Cash Flow	N/A	N/A	-$40.9M-16.9%	-$35.0M-11.6%	-$31.4M-92.9%	-$16.3M
Investing Cash Flow	-$132K+78.0%	-$600K-4094.6%	-$14K-1.7%	-$14K+89.2%	-$130K-52.0%	-$86K
Financing Cash Flow	$4.8M+10.9%	$4.3M-3.2%	$4.5M+187.5%	-$5.1M-106.3%	$82.0M+90.4%	$43.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$579K+273.9%	-$333K+25.4%	-$446K+67.6%	-$1.4M-23.1%	-$1.1M+3.1%	-$1.2M+54.2%	-$2.5M+77.0%	-$10.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$0	N/A	N/A	$0	N/A	N/A
Financing Cash Flow	$196K+222.3%	-$160K-1.8%	-$157K-1.8%	-$155K-102.9%	$5.3M	$0-100.0%	$2.5M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HEPA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-310.3%	N/A	-672.0%-587.4pp	-84.6%-49.5pp	-35.2%+15.0pp	-50.2%
Return on Assets	-269.6%	N/A	-270.4%-200.3pp	-70.0%-38.5pp	-31.6%+10.2pp	-41.8%
Current Ratio	10.25+9.7	0.51-2.8	3.31-3.9	7.16-4.7	11.88+2.7	9.15
Debt-to-Equity	0.15+2.0	-1.87-3.4	1.49+1.3	0.21+0.1	0.11-0.1	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-43.7%	N/A	-14.2%+13.3pp	-27.5%+129.3pp	-156.7%	N/A	-1196.5%-1086.3pp	-110.2%
Return on Assets	-30.0%	N/A	-12.6%+10.5pp	-23.1%+73.5pp	-96.6%	N/A	-131.0%-65.7pp	-65.3%
Current Ratio	3.68-6.6	10.25-0.5	10.77+3.2	7.60+0.8	6.75+6.2	0.51-0.8	1.30-4.3	5.62
Debt-to-Equity	0.46+0.3	0.15+0.0	0.13-0.1	0.19-0.4	0.62+2.5	-1.87-12.0	10.14+9.4	0.69
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Regen Biopharma RGBP

$154K

Emmaus Life Scie EMMA

$702K

Bio-Path Hldgs Inc BPTH

$4.7M

LadRx LADX

$579K

Therapeutic Solutions Intl Inc TSOI

$512K

Frequently Asked Questions

Is Hepion Pharmaceuticals Inc profitable?

No, Hepion Pharmaceuticals Inc (HEPA) reported a net income of -$8.3M in fiscal year 2025.

What is Hepion Pharmaceuticals Inc's return on equity (ROE)?

Hepion Pharmaceuticals Inc (HEPA) has a return on equity of -310.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hepion Pharmaceuticals Inc's operating cash flow?

Hepion Pharmaceuticals Inc (HEPA) generated -$3.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hepion Pharmaceuticals Inc's total assets?

Hepion Pharmaceuticals Inc (HEPA) had $3.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Hepion Pharmaceuticals Inc spend on research and development?

Hepion Pharmaceuticals Inc (HEPA) invested $446K in research and development during fiscal year 2025.

How many shares does Hepion Pharmaceuticals Inc have outstanding?

Hepion Pharmaceuticals Inc (HEPA) had 12M shares outstanding as of fiscal year 2025.

What is Hepion Pharmaceuticals Inc's current ratio?

Hepion Pharmaceuticals Inc (HEPA) had a current ratio of 10.25 as of fiscal year 2025, which is generally considered healthy.

What is Hepion Pharmaceuticals Inc's debt-to-equity ratio?

Hepion Pharmaceuticals Inc (HEPA) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hepion Pharmaceuticals Inc's return on assets (ROA)?

Hepion Pharmaceuticals Inc (HEPA) had a return on assets of -269.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Hepion Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Hepion Pharmaceuticals Inc (HEPA) had $1.8M in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Hepion Pharmaceuticals Inc's Piotroski F-Score?

Hepion Pharmaceuticals Inc (HEPA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hepion Pharmaceuticals Inc's earnings high quality?

Hepion Pharmaceuticals Inc (HEPA) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Hepion Pharmaceuticals Inc?

Hepion Pharmaceuticals Inc (HEPA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.